These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. [ON THE THERAPY OF HYPEROXALURIA AND SO-CALLED IDIOPATHIC HYPERCALCIURIA]. CHWALLA R Z Urol; 1963; 56():421-7. PubMed ID: 14086383 [No Abstract] [Full Text] [Related]
35. Influence of the calcium content of the diet on the incidence of mild hyperoxaluria in idiopathic renal stone formers. Jaeger P; Portmann L; Jacquet AF; Burckhardt P Am J Nephrol; 1985; 5(1):40-4. PubMed ID: 3970077 [TBL] [Abstract][Full Text] [Related]
36. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Takei K; Ito H; Masai M; Kotake T Urol Int; 1998; 61(3):192-5. PubMed ID: 9933846 [TBL] [Abstract][Full Text] [Related]
37. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258 [TBL] [Abstract][Full Text] [Related]
38. Vitamin B6 metabolites in idiopathic calcium stone formers: no evidence for a link to hyperoxaluria. Kaelin A; Casez JP; Jaeger P Urol Res; 2004 Feb; 32(1):61-8. PubMed ID: 14628106 [TBL] [Abstract][Full Text] [Related]
39. A porcine model of calcium oxalate kidney stone disease. Mandel NS; Henderson JD; Hung LY; Wille DF; Wiessner JH J Urol; 2004 Mar; 171(3):1301-3. PubMed ID: 14767337 [TBL] [Abstract][Full Text] [Related]
40. Protective impact of resveratrol in experimental rat model of hyperoxaluria. Oksay T; Yunusoğlu S; Calapoğlu M; Aydın Candan I; Onaran İ; Ergün O; Özorak A Int Urol Nephrol; 2017 May; 49(5):769-775. PubMed ID: 28185107 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]